Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Alvotech’s Japanese Ustekinumab Nod Is ‘First For Global Markets’

Stelara Biosimilar AVT04 To Be Commercialized By Partner Fuji Pharma

Executive Summary

Following the formation of their partnership nearly five years ago, Alvotech and Fuji have together welcomed approval in Japan for Alvotech’s biosimilar to Stelara (ustekinumab).

You may also be interested in...

Alvotech Notches Up Another Stelara Biosimilar Approval – In Canada

Alvotech and local partner Jamp Pharma have received the first Canadian approval for an ustekinumab biosimilar rival to Stelara in the form of Jamteki, with Health Canada’s marketing authorization following earlier nods for Alvotech’s AVT04 candidate in other geographies.

Trailblazer Amgen Scoops First US Stelara Biosimilar – With Interchangeability

With its portfolio of biosimilars continuing to grow, Amgen has received the first approval in the US for a biosimilar to Stelara – weeks after Alvotech/Teva was hit with a complete response letter.

Alvotech Receives CRL From FDA Over Ustekinumab Filing

Alvotech has announced that, “as expected”, its US filing for its AVT04 ustekinumab candidate has resulted in a complete response letter from the FDA over manufacturing facility deficiencies, following similar knockbacks for its adalimumab biosimilar. However, the firm anticipates an inspection and a new goal date for the proposed Stelara rival long before its planned February 2025 launch date.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts